Has John Graham received payments from drug or device companies?

Yes. Drug and device makers reported $1,445 in general payments to John Graham across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Graham did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Graham come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Graham

Cardiovascular Disease · Indianapolis, INNPI 1669443198

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 25.7% of the total. Reporting peaked in 2019 at $1,020 and has fallen 98.3% since, to $17 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in IN, where the typical reported total is $2,452.

$1,445in general payments, 2019–2025

Across 118 payments — averaging $12.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$371
Novartis$203
AstraZeneca$177
Merz North America, Inc.$160
Pfizer$136
Boston Scientific$97
plus $299 from 10 others

What the payments were for

Food & beverage$1,43499%
Education$101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	43	$371
Novartis	18	$203
AstraZeneca	12	$177
Merz North America, Inc.	1	$160
Pfizer	14	$136
Boston Scientific	7	$97
Amgen	6	$74
E.r. Squibb & Sons, L.L.C.	4	$48
Sanofi-aventis U.S. LLC	3	$42
Amarin Pharma, Inc.	3	$40
Novo Nordisk	2	$29
Regeneron Healthcare Solutions, Inc.	1	$16
Bayer	1	$14
GSK	1	$13
Kowa Pharmaceuticals America, Inc.	1	$12
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XEOMIN$160

How this compares

$1,445 in reported general payments places this provider in the 40th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana →

Other cardiovascular disease in Indianapolis

John MillerIndianapolis$354K
David KovacichIndianapolis$327K
Vijay RaoIndianapolis$247K
Atul ChughIndianapolis$242K
James TrippiIndianapolis$239K
Christopher HealyIndianapolis$209K
Richard KovacsIndianapolis$136K
George LolayIndianapolis$128K
Onyedika IlonzeIndianapolis$125K
Noel DasguptaIndianapolis$122K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →